 This post-hoc analysis evaluated the effectiveness of supplementing dichotomous efficacy outcomes with residual disease activity in patients with moderate to severe park psoriasis treated with Tildrachysumab 100 milligrams or placebo. The results showed that posi scores were more reliable than percentage posi improvement, and this may explain efficacy disparities between clinical trials and practice. Supplementing dichotomous posi improvement with posi scores and consideration of patient treatment goals could facilitate clinical decisions. This article was offered by K. B. Gordon, K. Rye, J. J. Crowley, and others.